{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:05:19Z","timestamp":1790089519603,"version":"4.0.1"},"reference-count":271,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.autrev.2024.103638","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T21:11:13Z","timestamp":1726175473000},"page":"103638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment strategies for Spondyloarthritis: Implementation of precision medicine \u2013 Or \u201cone size fits all\u201d concept?"],"prefix":"10.1016","volume":"23","author":[{"given":"Fabian","family":"Proft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba Izci","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10089","key":"10.1016\/j.autrev.2024.103638_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103638_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.berh.2018.07.012","article-title":"The role of HLA-B*27 in spondyloarthritis","volume":"31","author":"Colbert","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"14","key":"10.1016\/j.autrev.2024.103638_bb0040","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-018-0971-x","article-title":"Beyond the TNF-\u03b1 inhibitors: new and emerging targeted therapies for patients with axial Spondyloarthritis and their relation to pathophysiology","volume":"78","author":"Pedersen","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0050","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0065","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0070","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000153","article-title":"Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0080","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","article-title":"Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort","volume":"71","author":"Chung","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jbspin.2011.06.005","article-title":"On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study","volume":"79","author":"Sudre","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0090","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0095","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-016-3549-5","article-title":"Benefit of health education by a training nurse in patients with axial and\/or peripheral psoriatic arthritis: a systematic literature review","volume":"36","author":"Candelas","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103638_bb0100","article-title":"Physiotherapy interventions for ankylosing spondylitis","volume":"1","author":"Dagfinrud","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.berh.2014.10.003","article-title":"Nonpharmacologic therapies in spondyloarthritis","volume":"28","author":"Reimold","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","article-title":"Clinical tools to assess and monitor Spondyloarthritis","volume":"17","author":"Landew\u00e9","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0115","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00296-014-2965-7","article-title":"Exercise therapy for spondyloarthritis: a systematic review","volume":"34","author":"O\u2019Dwyer","year":"2014","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2015.08.003","article-title":"Exercise for ankylosing spondylitis: an evidence-based consensus statement","volume":"45","author":"Millner","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/acr.20415","article-title":"Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness?","volume":"63","author":"Dagfinrud","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0130","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3899\/jrheum.150721","article-title":"Nonsteroidal Antiinflammatory drugs for axial Spondyloarthritis: a Cochrane review","volume":"43","author":"Kroon","year":"2016","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0135","first-page":"Cd010952","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","author":"Kroon","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0140","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","article-title":"Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study","volume":"163","author":"Haroon","year":"2015","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0150","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","article-title":"Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis","volume":"49","author":"Escalas","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0155","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","article-title":"Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials","volume":"75","author":"Wang","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0165","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/rheumatology\/keh713","article-title":"The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis","volume":"44","author":"Barkham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb0170","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0180","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/ard.2004.029611","article-title":"Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis","volume":"64","author":"Gossec","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11926-017-0633-0","article-title":"Therapies of early, advanced, and late onset forms of axial Spondyloarthritis, and the need for treat to target strategies","volume":"19","author":"Akkoc","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0195","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0200","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/0016-5085(93)90667-2","article-title":"Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans","volume":"104","author":"Bjarnason","year":"1993","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0205","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3164\/jcbn.10-79","article-title":"The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine","volume":"48","author":"Matsui","year":"2011","journal-title":"J Clin Biochem Nutr"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","author":"Takeuchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0215","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1572-0241.2002.05592.x","article-title":"Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy","volume":"97","author":"Bonner","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0220","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/apt.14606","article-title":"Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn\u2019s disease and ulcerative colitis exacerbation","volume":"47","author":"Moninuola","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0225","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1302\/0301-620X.85B5.13970","article-title":"Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion","volume":"85","author":"Burd","year":"2003","journal-title":"J Bone Joint Surg Br"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1302\/0301-620X.80B2.0800259","article-title":"Indomethacin versus radiation therapy for prophylaxis against heterotopic ossification in acetabular fractures: a randomised, prospective study","volume":"80","author":"Moore","year":"1998","journal-title":"J Bone Joint Surg Br"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0235","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/17453670510045309","article-title":"Do non-steroidal anti-inflammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty","volume":"76","author":"Persson","year":"2005","journal-title":"Acta Orthop"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.21170","article-title":"Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures","volume":"53","author":"Bhattacharyya","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0245","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0250","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1089\/scd.2009.0393","article-title":"The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells","volume":"19","author":"Yoon","year":"2010","journal-title":"Stem Cells Dev"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0255","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0260","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/art.39690","volume":"68","author":"Poddubnyy","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0265","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/art.39474","article-title":"Brief report: six-week treatment of axial Spondyloarthritis patients with an optimal dose of nonsteroidal Antiinflammatory drugs: early response to treatment in signal intensity on magnetic resonance imaging of the sacroiliac joints","volume":"68","author":"Varkas","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014591","volume":"7","author":"Proft","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0275","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.rdc.2012.08.005","article-title":"Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs","volume":"38","author":"Poddubnyy","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13075-014-0481-5","article-title":"Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study","volume":"16","author":"Dougados","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103638_bb0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/annrheumdis-2022-eular.568","volume":"81","author":"Proft","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 55","key":"10.1016\/j.autrev.2024.103638_bb0295","first-page":"S159","article-title":"Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Haibel","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0300","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3906\/sag-1401-79","article-title":"Treatment of ankylosing spondylitis","volume":"45","author":"Sari","year":"2015","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.autrev.2024.103638_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"10.1016\/j.autrev.2024.103638_bb0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"10370","key":"10.1016\/j.autrev.2024.103638_bb0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0320","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0325","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0330","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0335","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0340","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0345","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb0355","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0365","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-017-1493-8","article-title":"Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance","volume":"19","author":"Ghosh","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0370","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/ar4561","article-title":"The window of opportunity: a relevant concept for axial spondyloarthritis","volume":"16","author":"Robinson","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0375","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3899\/jrheum.081096","article-title":"Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis","volume":"36","author":"Mattey","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0380","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti\u2013tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0385","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","article-title":"Body weight, gender and response to TNF-\u03b1 blockers in axial spondyloarthritis","volume":"53","author":"Gremese","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0390","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","article-title":"Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry","volume":"55","author":"Glintborg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0395","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization--a step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0400","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.2004.029728","article-title":"Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?","volume":"64","author":"Wanders","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0405","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0410","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0415","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0420","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103638_bb0425","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20906040","article-title":"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review","volume":"12","author":"Baraliakos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0435","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/rheumatology\/kez363","article-title":"The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review","volume":"58","author":"Boers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0440","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0445","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"10142","key":"10.1016\/j.autrev.2024.103638_bb0450","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0455","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0460","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0465","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0470","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized","volume":"69","author":"Dougados","year":"2017","journal-title":"Placebo Control Study Arthritis Care Res"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0475","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0480","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0485","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.berh.2019.01.014","article-title":"Emerging treatment options for spondyloarthritis","volume":"32","author":"Torgutalp","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0490","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"26","key":"10.1016\/j.autrev.2024.103638_bb0495","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor","volume":"373","author":"Baeten","year":"2015","journal-title":"Ankylosing Spondylitis N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0500","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-019-1911-1","article-title":"Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison","volume":"21","author":"Braun","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0505","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"10.1016\/j.autrev.2024.103638_bb0510","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0515","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0520","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00393-020-00837-9","article-title":"Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis","volume":"80","author":"Lee","year":"2021","journal-title":"Z Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0525","first-page":"110","article-title":"Improvement of signs and symptoms of nonradiographic axial Spondyloarthritis in patients treated with Secukinumab: primary results of a randomized","volume":"73","author":"Deodhar","year":"2021","journal-title":"Placebo Control Phase III Study Arthritis Rheumatol"},{"issue":"10217","key":"10.1016\/j.autrev.2024.103638_bb0530","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0535","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103638_bb0540","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0545","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0550","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0555","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2024.103638_bb0560","first-page":"86","article-title":"OP0135\u00a0RISK OF CARDIOVASCULAR EVENTS UNDER JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE GERMAN RABBIT REGISTER","volume":"81","author":"Meissner","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0565","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"issue":"10214","key":"10.1016\/j.autrev.2024.103638_bb0570","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103638_bb0575","author":"AIR"},{"issue":"10349","key":"10.1016\/j.autrev.2024.103638_bb0580","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103638_bb0585","article-title":"Upadacitinib in active ankylosing spondylitis: 1-year results from the double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0590","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0595","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"10.1016\/j.autrev.2024.103638_bb0600","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2024.103638_bb0605","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103638_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials","author":"Tanaka","year":"2021","journal-title":"Modern Rheumatology"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0615","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103638_bb0620","series-title":"Filgotinib drops out of US arthritis race: Gilead ends bid for FDA approval","year":"2020"},{"key":"10.1016\/j.autrev.2024.103638_bb0625","article-title":"No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u2018physician-reported spondylitis\u2019?","author":"Braun","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0630","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001728","article-title":"Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study","volume":"7","author":"Lopez-Medina","year":"2021","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0635","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001450","article-title":"Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study","volume":"7","author":"Lopez-Medina","year":"2021","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0640","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6 Suppl 1","key":"10.1016\/j.autrev.2024.103638_bb0645","first-page":"52","article-title":"GRAPPA treatment recommendations: 2021 update","volume":"49","author":"Coates","year":"2022","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0650","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2024.103638_bb0655","article-title":"Psoriatic arthritis therapy: NSAIDs and traditional DMARDs","volume":"64","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0660","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0665","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0670","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor","volume":"53","author":"Choon","year":"2014","journal-title":"Malaysia Int J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0675","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0680","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0685","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0690","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis. A systematic review","volume":"33","author":"Soriano","year":"2006","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103638_bb0695","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0700","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0705","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb0710","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of Apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0715","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0720","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000669","article-title":"Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies","volume":"4","author":"Gladman","year":"2018","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0725","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"13","key":"10.1016\/j.autrev.2024.103638_bb0730","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.autrev.2024.103638_bb0735","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10162","key":"10.1016\/j.autrev.2024.103638_bb0740","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.autrev.2024.103638_bb0745","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"New England J Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0750","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/rheumatology\/key417","article-title":"Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity","volume":"58","author":"Landew\u00e9","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0755","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3899\/jrheum.180681","article-title":"Radiographic progression inhibition with intravenous golimumab in psoriatic arthritis: week 24 results of a phase III, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kavanaugh","year":"2019","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103638_bb0760","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0765","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0770","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0775","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0780","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0785","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/spondylitis Association of America\/Spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial Spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0790","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb0795","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","article-title":"A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial","volume":"69","author":"Dougados","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0800","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.160387","article-title":"Performance of 3 Enthesitis indices in patients with peripheral Spondyloarthritis during treatment with adalimumab","volume":"44","author":"Mease","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103638_bb0805","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0810","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled Phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0815","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0820","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0825","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0830","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous Golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9999","key":"10.1016\/j.autrev.2024.103638_bb0835","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"10235","key":"10.1016\/j.autrev.2024.103638_bb0840","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0845","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"10.1016\/j.autrev.2024.103638_bb0850","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0855","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2024.103638_bb0860","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2022-eular.536","article-title":"OP0258IZOKIBEP (ABY-035) in patients with active psoriatic arthritis \u2013 16-week results from a phase 2 study","volume":"81","author":"Behrens","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0865","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00393-017-0355-8","article-title":"Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis","volume":"77","author":"Song","year":"2018","journal-title":"Z Rheumatol"},{"issue":"9894","key":"10.1016\/j.autrev.2024.103638_bb0870","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb0875","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb0880","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0885","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10230","key":"10.1016\/j.autrev.2024.103638_bb0890","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.autrev.2024.103638_bb0895","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb0900","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103638_bb0905","first-page":"31","article-title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives","volume":"8","author":"Noisette","year":"2018","journal-title":"Psoriasis (Auckl)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb0910","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0915","first-page":"301","article-title":"Efficacy of anti-tumour necrosis factor-\u03b1 monoclonal antibodies in patients with non-infectious anterior uveitis","volume":"37","author":"Fabiani","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb0920","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0925","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0930","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - the GO-EASY study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb0935","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0940","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0945","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of uveitis in Secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2024.103638_bb0950","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb0955","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2024.103638_bb0960","first-page":"614","article-title":"POS0668LOW uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2B\/3 trials","volume":"82","author":"Rudwaleit","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb0965","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb0970","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0975","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/ecco-jcc\/jjz167","article-title":"Two cases of successful Ustekinumab treatment for non-infectious uveitis associated with Crohn\u2019s disease","volume":"14","author":"Chateau","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb0980","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2013.03.031","article-title":"A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis","volume":"69","author":"Lebwohl","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.autrev.2024.103638_bb0985","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"issue":"9494","key":"10.1016\/j.autrev.2024.103638_bb0990","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb0995","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2024.103638_bb1000","article-title":"Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review","author":"Conforti","year":"2020","journal-title":"J Dermatolog Treat:1\u20138"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb1015","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1020","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bjd.12404","article-title":"Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)","volume":"168","author":"Reich","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103638_bb1025","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/jid.2013.78","article-title":"Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action","volume":"133","author":"Nast","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"9993","key":"10.1016\/j.autrev.2024.103638_bb1035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","article-title":"Efficacy and safety of Ixekizumab with or without methotrexate in biologic-Na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study","volume":"7","author":"Smolen","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"10273","key":"10.1016\/j.autrev.2024.103638_bb1055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.autrev.2024.103638_bb1060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103638_bb1070","series-title":"Announces European Commission Approval of BIMZELX [\u00ae]\u25bc(bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis","author":"Narang","year":"2024"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103638_bb1080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med"},{"issue":"10275","key":"10.1016\/j.autrev.2024.103638_bb1085","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103638_bb1090","series-title":"OP0223 efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PsA-2): A double-blind, randomized controlled phase 3 trial","author":"Genovese","year":"2020"},{"issue":"9993","key":"10.1016\/j.autrev.2024.103638_bb1095","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2024.103638_bb1100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb1105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14728214.2020.1745773","article-title":"Emerging systemic drugs in the treatment of plaque psoriasis","volume":"25","author":"Balogh","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.autrev.2024.103638_bb1115","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","author":"Armstrong","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103638_bb1120","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"9625","key":"10.1016\/j.autrev.2024.103638_bb1125","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.autrev.2024.103638_bb1130","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.autrev.2024.103638_bb1140","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"issue":"10148","key":"10.1016\/j.autrev.2024.103638_bb1145","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"10198","key":"10.1016\/j.autrev.2024.103638_bb1150","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb1155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1160","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb1165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb1170","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"10.1016\/j.autrev.2024.103638_bb1175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1180","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1185","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10091","key":"10.1016\/j.autrev.2024.103638_bb1190","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2024.103638_bb1195","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb1200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1205","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb1210","first-page":"111","article-title":"Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase","volume":"46","author":"Masuda","year":"1995","journal-title":"J Clin Lab Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1215","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1220","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb1230","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb1235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb1240","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2010.01.014","article-title":"Continuous therapy with certolizumab pegol maintains remission of patients with Crohn\u2019s disease for up to 18 months","volume":"8","author":"Lichtenstein","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.autrev.2024.103638_bb1245","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s disease cA2 study group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1250","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ecco-jcc\/jjx176","article-title":"The unfinished symphony: Golimumab therapy for anti-tumour necrosis factor refractory Crohn\u2019s disease","volume":"12","author":"Greener","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.autrev.2024.103638_bb1255","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"10S","key":"10.1016\/j.autrev.2024.103638_bb1260","article-title":"S736 efficacy and safety of Upadacitinib induction therapy in patients with moderately to severely active Crohn\u2019s disease: results from a randomized phase 3 U-EXCEL study","volume":"117","author":"Loftus","year":"2022","journal-title":"Off J Am College Gastroenterol"},{"issue":"7)","key":"10.1016\/j.autrev.2024.103638_bb1265","article-title":"867f: efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active Crohn\u2019s disease who failed prior biologics: results from a randomized phase 3 U-exceed study","volume":"162","author":"Colombel","year":"2022","journal-title":"Gastroenterology"},{"issue":"10066","key":"10.1016\/j.autrev.2024.103638_bb1270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1275","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.autrev.2024.103638_bb1280","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"20","key":"10.1016\/j.autrev.2024.103638_bb1285","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103638_bb1290","article-title":"775a Risankizumab induction therapy in patients with moderate-to-severe Crohn\u2019s disease with intolerance or inadequate response to conventional and\/or biologic therapy: results from the phase 3 ADVANCE study","volume":"161","author":"D\u2019Haens","year":"2021","journal-title":"Gastroenterology"},{"issue":"8S","key":"10.1016\/j.autrev.2024.103638_bb1295","first-page":"64","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Crohn\u2019s disease: week 12 interim analyses from the phase 2 galaxi 1 study","volume":"8","author":"Sandborn","year":"2020","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb1300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn\u2019s disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1305","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103638_bb1310","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"issue":"23","key":"10.1016\/j.autrev.2024.103638_bb1315","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb1320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.autrev.2024.103638_bb1325","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2024.103638_bb1330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.autrev.2024.103638_bb1335","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"10292","key":"10.1016\/j.autrev.2024.103638_bb1340","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2024.103638_bb1345","doi-asserted-by":"crossref","first-page":"S021","DOI":"10.1093\/ecco-jcc\/jjab075.022","article-title":"OP23 efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103638_bb1350","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJMc1915042","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"382","author":"Sands","year":"2020","journal-title":"Reply N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2024.103638_bb1355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:00:41Z","timestamp":1728478841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":271,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1568997224001290"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103638","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies for Spondyloarthritis: Implementation of precision medicine \u2013 Or \u201cone size fits all\u201d concept?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103638"}}